ClinicalTrials.gg
RecruitingNCT06513000Updated Jul 22, 2024

Dryness Difference Between Before and After Phacoemulsification

An observational study in Dry Eye, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Dry Eye Syndromes with a site in Egypt — 6 open to participants now, 7 under way, none of them phase 3. Dry Eye Syndromes · Egypt.

Started
2024
with 4 others
Observational
7 of 24
2 open now
Registered
12th of 24
by date
Lead sponsor
3 of 24
Sohag University

Among the 24 studies in Dry Eye Syndromes with a site in Egypt, this one is one of 5 that started in 2024, is one of 7 observational ones, and was the 12th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

6 of the 24 studies in Dry Eye Syndromes with a site in Egypt are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 45 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Dry Eye Syndromes with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this study is to compare tear film and tear film secretion before and after phacoemulsificaton cataract surgery

Read the detailed description

The tear film is a thin fluid layer overlies the ocular surface and provides the interface between the ocular surface and the external environment.

  • It consists of three layers (lipid, aqueous and mucous) which act together to protect the corneal and conjunctival tissues and keeping them healthy.
  • The superficial lipid layer is secreted by meibomian glands and functions as a smooth optical surface, reduces surface tension of the tear film, prevents anterior migration of aqueous tears on to the lid margin and retards evaporation .
  • The Mucous layer is secreted by the goblet cells of the conjunctiva. It contains mucins that is very essential for lubrication, and wetting.
  • The aqueous tear layer is mainly produced by the main lacrimal glands with small amounts produced by the goblet cells in the conjunctiva and accessory lacrimal glands and This layer acts by providing oxygen and nutrients to the avascular corneal tissue, washing away tissue debris, toxins, and foreign bodies, and also protecting the ocular surface from microbes.
  • Cataract is the common cause of vision loss in the developing countries, also its rate of incidence increases with aging. So it is essential for those patients to undergo cataract surgeries to improve their vision and protect them from blindness.
  • Phacoemulsification is the most recent cataract surgery at which a small incision is done then the ultrasonic power is used to fragment and emulsify the cataract. It was first introduced by Dr. Charlies Kelman and now Most surgeons prefer phacoemulsification surgery because of less postoperative astigmatism, faster stabilization of vision and refraction, and less postoperative inflammation
  • Some surgical interventions related to the anterior segment may also cause dry eye and aggravate the symptoms of pre-existing dry eye, like PRK, LASIK, and cataract surgery by extra capsular cataract extraction, because a large incision is created in the eye during the procedure that sometimes damages the cornea and also can occur with phacoemulsification with a smaller incision.
  • There are many tests that are used to estimate the degree of dryness and its severity which measure tear stability, tear production, and the presence of ocular surface disorders like Schirmer's test , which is used to evaluate tear production and the severity of dry eye by estimating the amount of special filter paper wetting that is put in the lower fornix for 5 minutes, and the Tears Break Up Time test, which is important to evaluate the tear film stability and evaporation.
  • In this study we aim to evaluate dry eye affection after phacoemulsification whether it is worsen or not and the degree of increased dryness especially that dry eye syndrome is very common in our community and how phacoemulsification is now a frequent and preferred operation.

After taking a good detailed history The following assessments were performed in each patient before surgery and at the 2-week and 1-, 3-, and 6-month follow-up visits by the following tests:

  1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability.
  2. Non-invasive tear meniscus height.
  3. Evaluation of Meibomian glands function.
  4. Lipid layer thickness.
  5. Eyelid margin.
  6. Analysis of conjunctival hyperemia.
  7. Cornea sodium fluorescein staining.

    • Schirmer I test, a measure of basic and reflex tear secretion, was performed without anesthesia. This test was performed by placing Schirmer strips over the lower lid margin; the strip wetting was measured and recorded in millimeters.
    • Dry eye symptoms patients were classified as having dry eye disease if they reported experiencing one or more of the primary symptoms (soreness, scratchiness, dryness, grittiness, burning) often or constantly, the TBUT value was less than 10 seconds, and in Schirmer test I there is less than 10 mm wetting of filter paper for a period of 6 months or more after surgery.
    • Visual acuity before and after surgery.
    • Anterior segment examination by slit lamp.
03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

this study included 100 cataract patients, with age above 45 years old who underwent uncomplicated phacoemulsification surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cataract patients.
  • Cases within age > 45 years old.

Exclusion criteria

Exclusion criteria:

  • Patients with ocular surface diseases and eyelid abnormality.
  • Patients receive ocular or systemic medications, that interfere with tear film production and stability (e.g. topical eye drops that contain preservatives, antihistaminic drugs, anticholinergic drugs, pills).
  • Patients with systemic diseases like diabetes, HTN, rheumatoid arthritis. - Patients underwent previous ocular surgeries that interfere with tears instability or production (e.g. refractive surgery, keratoplasty, eyelid surgeries, pterygium excision).
  • Patients with a history of trauma, chemical burn, overusing contact lens (due to damaging the conjunctiva and the goblet cells, also corneal sensitivity reduction).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testDry eye diagnostic system

    following tests: 1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability. 2. Non-invasive tear meniscus height. 3. Evaluation of Meibomian glands function. 4. Lipid layer thickness. 5. Eyelid margin. 6. Analysis of conjunctival hyperemia. 7. Cornea sodium fluorescein staining. 8. Schirmer I test

06

What researchers measure

Primary outcomes

  1. Evaluation Of Dryness Post Phacoemulcification In Non Complicated Cases using tear film break up time in seconds.

    Analysis of dryness before and after uncomplicated phacoemulsification using tear film break up time in seconds.

    Time frame: Before the operation and 2-week and 1, 3, and 6 month after the operation

  2. Evaluation Of Dryness Post Phacoemulcification In Non Complicated Cases using tear meniscus height in millimeters.

    Analysis of dryness before and after uncomplicated phacoemulsification using tear meniscus height in millimeters.

    Time frame: Before the operation and 2-week and 1, 3, and 6 month after the operation

  3. Evaluation Of Dryness Post Phacoemulcification In Non Complicated Cases using Lipid layer thickness in nanometers.

    Analysis of dryness before and after uncomplicated phacoemulsification using Lipid layer thickness in nanometers..

    Time frame: Before the operation and 2-week and 1, 3, and 6 month after the operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Qin Y, Pan ZQ. [Recent advances in dry eye: etiology, pathogenesis and management]. Zhonghua Yan Ke Za Zhi. 2013 Sep;49(9):857-63. Chinese. PubMed 24330938 ↗
  • Moss SE, Klein R, Klein BE. Long-term incidence of dry eye in an older population. Optom Vis Sci. 2008 Aug;85(8):668-74. doi: 10.1097/OPX.0b013e318181a947. PubMed 18677233 ↗
  • Mertzanis P, Abetz L, Rajagopalan K, Espindle D, Chalmers R, Snyder C, Caffery B, Edrington T, Simpson T, Nelson JD, Begley C. The relative burden of dry eye in patients' lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005 Jan;46(1):46-50. doi: 10.1167/iovs.03-0915. PubMed 15623753 ↗
  • Pflugfelder SC, Stern ME. Biological functions of tear film. Exp Eye Res. 2020 Aug;197:108115. doi: 10.1016/j.exer.2020.108115. Epub 2020 Jun 16. PubMed 32561483 ↗
  • Xue W, Zhu MM, Zhu BJ, Huang JN, Sun Q, Miao YY, Zou HD. Long-term impact of dry eye symptoms on vision-related quality of life after phacoemulsification surgery. Int Ophthalmol. 2019 Feb;39(2):419-429. doi: 10.1007/s10792-018-0828-z. Epub 2018 Feb 1. PubMed 29392638 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Feb 2025, 7 months after the start.

Of 53 non-industry observational studies under Dry Eye Syndromes, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 7 months is below that.

Counting every sponsor, half of 69 studies reached it within 12 months; a quarter within 5 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 22, 2024
StartActual
Jul 12, 2024
Primary completionEst.
Feb 2025
CompletionEst.
Mar 2025
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06513000
Lead sponsor
Sohag University
Responsible party
Mohamed Samir (Doctor, Sohag University) — Principal investigator
First posted
Jul 22, 2024
Start date
Jul 12, 2024
Primary completion
Feb 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Jul 22, 2024

Study contacts

Mohamed Samir zayed, Resident
Contact
Doc.sad.2000@gmail.com
01111485309 ext. 002
Hatem Gamal eldeen, Professor
study director · Sohag University
Mahmoud Mohamed farouk, Professor
study chair · Sohag University
Hany Mahmoud, Lecturer
study chair · Sohag University
Mohamed samir zayed, resident
principal investigator · Tahta ophthalmology hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion